ERBB2 and metastatic colorectal cancer: Indeed, there are three currently approved antibodies in clinical use: herceptin (an anti-HER2 approved to treat breast cancer overexpressing HER2), cetuximab, and panitumumab (anti-EGFR approved for treating metastatic colorectal cancer) [3].